NCT03394508View on ClinicalTrials.gov

The Safety and Efficacy of Intralymphatic Immunotherapy in Pollen Allergic Adolescents and Young Adults With Asthma

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
RhinitisAsthmaAllergy
Interventions
DRUG

ALK Alutard birch or 5-grasses

Intralymphatic injection with 1000 units. 3 injections with 4-5 weeks interval (0,1 ml) and one additional booster injection with 1000 units before the second pollen season.

DRUG

ALK diluent 0,3% human albumin

Intralymphatic injection with 0.1 ml. 3 injections with 4-5 weeks interval

All Listed Sponsors
lead

Karolinska Institutet

OTHER

NCT03394508 - The Safety and Efficacy of Intralymphatic Immunotherapy in Pollen Allergic Adolescents and Young Adults With Asthma | Biotech Hunter | Biotech Hunter